Becker Capital Management Inc. Acquires 11,192 Shares of Sanofi $SNY

Becker Capital Management Inc. lifted its stake in Sanofi (NASDAQ:SNY) by 2.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 568,400 shares of the company’s stock after acquiring an additional 11,192 shares during the period. Becker Capital Management Inc.’s holdings in Sanofi were worth $27,459,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently bought and sold shares of SNY. Brighton Jones LLC raised its stake in shares of Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after buying an additional 1,869 shares during the period. Blair William & Co. IL purchased a new stake in Sanofi in the 1st quarter worth approximately $246,000. Charles Schwab Investment Management Inc. raised its stake in Sanofi by 32.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 200,615 shares of the company’s stock worth $11,126,000 after acquiring an additional 48,670 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Sanofi by 6.7% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,032 shares of the company’s stock valued at $224,000 after purchasing an additional 253 shares in the last quarter. Finally, Townsquare Capital LLC lifted its holdings in Sanofi by 5.7% during the first quarter. Townsquare Capital LLC now owns 32,821 shares of the company’s stock valued at $1,820,000 after purchasing an additional 1,760 shares in the last quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Up 0.9%

Shares of SNY stock opened at $48.26 on Thursday. The company’s fifty day simple moving average is $49.94 and its two-hundred day simple moving average is $49.09. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12. The stock has a market cap of $118.50 billion, a P/E ratio of 11.30, a PEG ratio of 1.30 and a beta of 0.44. The company has a quick ratio of 0.30, a current ratio of 1.06 and a debt-to-equity ratio of 0.16.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 24th. The company reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $1.31. The firm had revenue of $15.46 billion for the quarter, compared to analysts’ expectations of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The business’s revenue was down 7.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.25 earnings per share. Analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Analysts Set New Price Targets

SNY has been the subject of a number of analyst reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Sanofi in a research note on Monday, December 1st. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. HSBC reissued a “buy” rating on shares of Sanofi in a report on Wednesday. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday. Finally, Guggenheim cut Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.